Literature DB >> 18040781

New insights into the neuroimmunity of SIV infection by magnetic resonance spectroscopy.

R Gilberto González1, Jane B Greco, Julian He, Margaret R Lentz, Shawn O'Neil, Sarah J Pilkenton, Eva M Ratai, Susan Westmoreland.   

Abstract

(1)H magnetic resonance spectroscopy (MRS) was employed to noninvasively monitor neuronal injury in eight rhesus macaques infected with simian immunodeficiency virus (SIV), whose immune system was compromised by CD8 T lymphocyte depletion and treated with highly active antiretroviral therapy (HAART). SIV infection and CD8 depletion resulted in a rapid decline in cerebral N-acetylaspartate (NAA) levels, a sensitive marker of neuronal health. Within 3 months of SIV infection and CD8 depletion, four animals developed AIDS and severe SIV encephalitis. The other four macaques underwent daily doses of HAART beginning 4 weeks after infection/CD8 depletion. HAART involved drugs that do not penetrate the central nervous system (CNS) including 9-[2(R)-(phosphonomethoxy)propyl]adenine and a racemic mixture of D: -L: -enantiomers of 2',3'-dideoxy-5-fluoro-3'thiacytidine. HAART resulted in reversal of NAA/Cr decline after 4 weeks of therapy, and no virus or encephalitis was found in brain samples analyzed. These results indicate that the CNS injury in AIDS is entirely dependent on events involving the peripheral immune system mediated by trafficking of SIV-infected monocytes into the brain. The rapid decline in NAA/Cr with SIV infection/CD8 depletion and its rapid recovery with HAART suggest that: (1) infected monocyte turnover in the CNS is rapid, occurring in days to weeks; (2) there are endogenous mechanisms that reverse neuronal injury; and (3) a threshold level of infected monocytes/macrophages in the CNS is required to overcome the neuronal recovery processes. These observations explain the clinical success of antiretroviral therapy in reducing the incidence of HIV-associated dementia and minor cognitive/motor disorder and suggest novel targets for drug development.

Entities:  

Mesh:

Year:  2006        PMID: 18040781     DOI: 10.1007/s11481-006-9016-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  55 in total

1.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

2.  Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy.

Authors:  L L Cheng; M J Ma; L Becerra; T Ptak; I Tracey; A Lackner; R G González
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain.

Authors:  Margaret R Lentz; John P Kim; Susan V Westmoreland; Jane B Greco; Robert A Fuller; Eva M Ratai; Julian He; Prabhat K Sehgal; Elkan F Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González
Journal:  Radiology       Date:  2005-03-29       Impact factor: 11.105

4.  1H NMR chemical shift selective (CHESS) imaging.

Authors:  A Haase; J Frahm; W Hänicke; D Matthaei
Journal:  Phys Med Biol       Date:  1985-04       Impact factor: 3.609

Review 5.  Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling.

Authors:  M H Baslow
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

6.  Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain.

Authors:  S Lacroix; S Rivest
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

7.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.

Authors:  L Chang; T Ernst; M Leonido-Yee; M Witt; O Speck; I Walot; E N Miller
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

Review 8.  Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring.

Authors:  Michael D Boska; R Lee Mosley; Mehmood Nawab; Jay A Nelson; Marina Zelivyanskaya; Larisa Poluektova; Mariano Uberti; Huanyu Dou; Travis B Lewis; Howard E Gendelman
Journal:  Curr HIV Res       Date:  2004-01       Impact factor: 1.581

9.  Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging.

Authors:  D J Meyerhoff; S MacKay; L Bachman; N Poole; W P Dillon; M W Weiner; G Fein
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

Review 10.  Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance?

Authors:  Malcolm J Avison; Avi Nath; Joseph R Berger
Journal:  Trends Neurosci       Date:  2002-09       Impact factor: 13.837

View more
  7 in total

1.  Brain creatine elevation and N-Acetylaspartate reduction indicates neuronal dysfunction in the setting of enhanced glial energy metabolism in a macaque model of neuroAIDS.

Authors:  Eva-Maria Ratai; Lakshmanan Annamalai; Tricia Burdo; Chan-Gyu Joo; Jeffrey P Bombardier; Robert Fell; Reza Hakimelahi; Julian He; Margaret R Lentz; Jennifer Campbell; Elizabeth Curran; Elkan F Halpern; Eliezer Masliah; Susan V Westmoreland; Kenneth C Williams; R Gilberto González
Journal:  Magn Reson Med       Date:  2011-03-04       Impact factor: 4.668

2.  Early detection of neuropathophysiology using diffusion-weighted magnetic resonance imaging in asymptomatic cats with feline immunodeficiency viral infection.

Authors:  Daniel S Bucy; Mark S Brown; Helle Bielefeldt-Ohmann; Jesse Thompson; Annette M Bachand; Michelle Morges; John H Elder; Sue Vandewoude; Susan L Kraft
Journal:  J Neurovirol       Date:  2011-07-23       Impact factor: 2.643

Review 3.  Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS.

Authors:  Leslie Crews; Margaret R Lentz; R Gilberto Gonzalez; Howard S Fox; Eliezer Masliah
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

Review 4.  Monocyte/macrophages and their role in HIV neuropathogenesis.

Authors:  Tricia H Burdo; Andrew Lackner; Kenneth C Williams
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 5.  Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.

Authors:  Jerel Fields; Wilmar Dumaop; T D Langford; Edward Rockenstein; E Masliah
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-08       Impact factor: 4.147

6.  Metabolic markers of neuronal injury correlate with SIV CNS disease severity and inoculum in the macaque model of neuroAIDS.

Authors:  Margaret R Lentz; Susan V Westmoreland; Vallent Lee; Eva-Maria Ratai; Elkan F Halpern; R Gilberto González
Journal:  Magn Reson Med       Date:  2008-03       Impact factor: 4.668

7.  Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

Authors:  Michael J Peluso; Dieter J Meyerhoff; Richard W Price; Julia Peterson; Evelyn Lee; Andrew C Young; Rudy Walter; Dietmar Fuchs; Bruce J Brew; Paola Cinque; Kevin Robertson; Lars Hagberg; Henrik Zetterberg; Magnus Gisslén; Serena Spudich
Journal:  J Infect Dis       Date:  2013-03-04       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.